cabotegravir/rilpivirine

Generic Name: cabotegravir sodium cabotegravir-rilpivirine

Brand Name: Vocabria and Cabenuva

Manufacturer: ViiV Healthcare ULC

Therapeutic Area: HIV-1 infection

Indications: HIV-1 infection

Manufacturer Requested Reimbursement Criteria¹: Vocabria (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically stable and suppressed HIV-1 RNA less than 50 copies/mL) as: an oral lead-in to assess tolerability of cabotegravir prior to initiating Cabenuva, oral bridging therapy for missed Cabenuva injections Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL).

Submission Type: Initial

Project Status: Complete

Companion Diagnostics: No

Date Recommendation Issued: July 22, 2020

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.